ALPMY vs. EXEL

Last updated Apr 1, 2026

Compare and contrast key facts about Astellas Pharma Inc (ALPMY) and Exelixis, Inc. (EXEL).

Performance

ALPMY vs. EXEL - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Astellas Pharma Inc (ALPMY) and Exelixis, Inc. (EXEL). The values are adjusted to include any dividend payments, if applicable.

ALPMY vs. EXEL - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
ALPMY Astellas Pharma Inc	22.05%	41.23%	-17.10%	-21.50%	-6.82%	5.38%	-9.34%	35.81%	-1.10%	-7.48%
EXEL Exelixis, Inc.	0.48%	31.62%	38.81%	49.56%	-12.25%	-8.92%	13.90%	-10.42%	-35.30%	103.89%

Fundamentals

Market Cap ALPMY : $29.15B EXEL : $12.41B
EPS ALPMY : $181.46 EXEL : $2.76
PE Ratio ALPMY : 0.09 EXEL : 15.94
PEG Ratio ALPMY : 0.00 EXEL : 0.28
PS Ratio ALPMY : 0.01 EXEL : 5.38
PB Ratio ALPMY : 0.02 EXEL : 5.74
Total Revenue (TTM) ALPMY : $2.08T EXEL : $2.32B
Gross Profit (TTM) ALPMY : $1.62T EXEL : $2.24B
EBITDA (TTM) ALPMY : $599.42B EXEL : $934.65M

Returns By Period

In the year-to-date period, ALPMY achieves a 22.05% return, which is significantly higher than EXEL's 0.48% return. Over the past 10 years, ALPMY has underperformed EXEL with an annualized return of 3.20%, while EXEL has yielded a comparatively higher 26.95% annualized return.

ALPMY

• 1D: 0.50%
• 1M: -1.76%
• YTD: 22.05%
• 6M: 49.08%
• 1Y: 67.91%
• 3Y*: 6.21%
• 5Y*: 1.96%
• 10Y*: 3.20%

EXEL

• 1D: 2.68%
• 1M: 7.34%
• YTD: 0.48%
• 6M: 6.89%
• 1Y: 21.02%
• 3Y*: 31.40%
• 5Y*: 13.76%
• 10Y*: 26.95%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

ALPMY vs. EXEL — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ALPMY

ALPMY Risk / Return Rank: 93
ALPMY Sharpe Ratio Rank: 94
ALPMY Sortino Ratio Rank: 93
ALPMY Omega Ratio Rank: 91
ALPMY Calmar Ratio Rank: 94
ALPMY Martin Ratio Rank: 93

EXEL

EXEL Risk / Return Rank: 57
EXEL Sharpe Ratio Rank: 57
EXEL Sortino Ratio Rank: 53
EXEL Omega Ratio Rank: 56
EXEL Calmar Ratio Rank: 58
EXEL Martin Ratio Rank: 58

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ALPMY vs. EXEL - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Astellas Pharma Inc (ALPMY) and Exelixis, Inc. (EXEL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	ALPMY	EXEL	Difference
Sharpe ratio Return per unit of total volatility	2.47	0.48	+1.99
Sortino ratio Return per unit of downside risk	3.26	0.97	+2.29
Omega ratio Gain probability vs. loss probability	1.41	1.14	+0.26
Calmar ratio Return relative to maximum drawdown	5.54	0.76	+4.78
Martin ratio Return relative to average drawdown	13.50	1.78	+11.72
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

ALPMY vs. EXEL - Sharpe Ratio Comparison

The current ALPMY Sharpe Ratio is 2.47, which is higher than the EXEL Sharpe Ratio of 0.48. The chart below compares the historical Sharpe Ratios of ALPMY and EXEL, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	ALPMY	EXEL	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	2.47	0.48	+1.99
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.08	0.38	-0.30
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.13	0.60	-0.48
Sharpe Ratio (All Time) Calculated using the full available price history	-0.14	0.07	-0.21

Correlation

The correlation between ALPMY and EXEL is 0.14, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

ALPMY vs. EXEL - Dividend Comparison

Neither ALPMY nor EXEL has paid dividends to shareholders.

	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
ALPMY Astellas Pharma Inc	0.00%	1.93%	2.56%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1.20%	2.18%
EXEL Exelixis, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Drawdowns

ALPMY vs. EXEL - Drawdown Comparison

The maximum ALPMY drawdown since its inception was -83.67%, smaller than the maximum EXEL drawdown of -97.38%. Use the drawdown chart below to compare losses from any high point for ALPMY and EXEL.

Drawdown Indicators

	ALPMY	EXEL	Difference
Max Drawdown Largest peak-to-trough decline	-83.67%	-97.38%	+13.71%
Max Drawdown (1Y) Largest decline over 1 year	-12.21%	-25.34%	+13.13%
Max Drawdown (5Y) Largest decline over 5 years	-49.11%	-41.47%	-7.64%
Max Drawdown (10Y) Largest decline over 10 years	-49.67%	-57.20%	+7.53%
Current Drawdown Current decline from peak	-70.04%	-10.58%	-59.46%
Average Drawdown Average peak-to-trough decline	-58.27%	-71.54%	+13.27%
Ulcer Index Depth and duration of drawdowns from previous peaks	5.01%	10.86%	-5.85%

Volatility

ALPMY vs. EXEL - Volatility Comparison

Astellas Pharma Inc (ALPMY) has a higher volatility of 9.35% compared to Exelixis, Inc. (EXEL) at 7.20%. This indicates that ALPMY's price experiences larger fluctuations and is considered to be riskier than EXEL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	ALPMY	EXEL	Difference
Volatility (1M) Calculated over the trailing 1-month period	9.35%	7.20%	+2.15%
Volatility (6M) Calculated over the trailing 6-month period	21.45%	26.65%	-5.20%
Volatility (1Y) Calculated over the trailing 1-year period	27.59%	43.83%	-16.24%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	25.16%	36.85%	-11.69%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	25.44%	44.88%	-19.44%

Financials

ALPMY vs. EXEL - Profitability Comparison

The chart below illustrates the profitability comparison between Astellas Pharma Inc and Exelixis, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

ALPMY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Astellas Pharma Inc reported a gross profit of 429.70B and revenue of 581.52B. Therefore, the gross margin over that period was 73.9%.

EXEL - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Exelixis, Inc. reported a gross profit of 572.18M and revenue of 598.66M. Therefore, the gross margin over that period was 95.6%.

ALPMY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Astellas Pharma Inc reported an operating income of 126.95B and revenue of 581.52B, resulting in an operating margin of 21.8%.

EXEL - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Exelixis, Inc. reported an operating income of 235.22M and revenue of 598.66M, resulting in an operating margin of 39.3%.

ALPMY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Astellas Pharma Inc reported a net income of 102.13B and revenue of 581.52B, resulting in a net margin of 17.6%.

EXEL - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Exelixis, Inc. reported a net income of 244.53M and revenue of 598.66M, resulting in a net margin of 40.9%.